血管紧张素II治疗难治性休克:一项匹配分析
该回顾性匹配分析纳入813例ICU成人休克患者,比较接受血管紧张素II与接受等效剂量非血管紧张素II升压药的历史和同期对照。血管紧张素II与30天死亡率(60% vs 56%;p=0.292)和90天死亡率(65% vs 63%;p=0.440)均无显著关联,5天SOFA评分变化相似。血管紧张素II未增加肾脏替代治疗(OR 1.39;95%CI 0.88-2.19;p=0.158)、机械通气(OR 1.50;95%CI 0.41-5.51;p=0.539)或血栓事件(OR 1.02;95%CI 0.71-1.48;p=0.912)风险。
要点
- 血管紧张素II与30天死亡率无关(60% vs 56%;p=0.292)。
- 血管紧张素II与90天死亡率无关(65% vs 63%;p=0.440)。
- 血管紧张素II未增加肾脏替代治疗风险(OR 1.39;95%CI 0.88-2.19;p=0.158)。
- 血管紧张素II未增加机械通气风险(OR 1.50;95%CI 0.41-5.51;p=0.539)。
- 血管紧张素II未增加血栓事件风险(OR 1.02;95%CI 0.71-1.48;p=0.912)。
适用人群与场景
- 813例成人休克患者,入住ICU并需要升压药支持。
- 多ICU、大型大学附属医院。
研究设计与关键结果
- 研究类型:回顾性匹配分析,比较血管紧张素II与接受等效剂量非血管紧张素II升压药的历史和同期对照。
- 样本量:813例成人休克患者。
- 主要终点:30天死亡率血管紧张素II组60% vs 对照组56%(p=0.292)。
- 次要终点:90天死亡率65% vs 63%(p=0.440);5天SOFA评分变化相似。
- 不良事件:肾脏替代治疗OR 1.39(95%CI 0.88-2.19;p=0.158);机械通气OR 1.50(95%CI 0.41-5.51;p=0.539);血栓事件OR 1.02(95%CI 0.71-1.48;p=0.912)。
证据类型、等级与局限
- 证据类型:回顾性匹配分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在重症休克患者中,血管紧张素II未改善死亡率或器官功能障碍,也未增加不良事件发生率;原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To determine if angiotensin II is associated with improved outcomes as measured by 30- and 90-day mortality as well as other secondary outcomes such as organ dysfunction and adverse events.
DESIGN: Retrospective, matched analysis of patients receiving angiotensin II compared with both historical and concurrent controls receiving equivalent doses of nonangiotensin II vasopressors.
SETTING: Multiple ICUs in a large, university-based hospital.
PATIENTS: Eight hundred thirteen adult patients with shock admitted to an ICU and requiring vasopressor support.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Angiotensin II use had no association with the primary outcome of 30-day mortality (60% vs 56%; p = 0.292). The secondary outcome of 90-day mortality was also similar (65% vs 63%; p = 0.440) as were changes in Sequential Organ Failure Assessment scores over a 5-day monitoring period after enrollment. Angiotensin II was not associated with increased rates of kidney replacement therapy (odds ratio [OR], 1.39; 95% CI, 0.88-2.19; p = 0.158) or receipt of mechanical ventilation (OR, 1.50; 95% CI, 0.41-5.51; p = 0.539) after enrollment, and the rate of thrombotic events was similar between angiotensin II and control patients (OR, 1.02; 95% CI, 0.71-1.48; p = 0.912).
CONCLUSIONS: In patients with severe shock, angiotensin II was not associated with improved mortality or organ dysfunction and was not associated with an increased rate of adverse events.
参考来源
- Smith LM, Mentz GB, Engoren MC, et al. Angiotensin II for the Treatment of Refractory Shock: A Matched Analysis. Crit Care Med. 2023. PMID: 37378469. doi:10.1097/CCM.0000000000005975
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。